Skip to main content

Table 1 Descriptive characteristics of all total hip replacement (THR) patients according to red blood cell transfusion within 8 days of surgery.

From: Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study

  Transfusion
n = 9,063
No transfusion
n = 19,024
Standardized mean difference***
Age (years)    
10-49 338 (3.7%) 1363 (7.2%) 0.18797
50-59 834 (9.2%) 3162 (16.6%) 0.22038
60-69 2098 (23.2%) 6334 (33.3%) 0.18585
70-79 3189 (35.2%) 5957 (31.3%) 0.11451
+80 2604 (28.7%) 2208 (11.6%) 0.42107
Sex    
Female 6440 (71.1%) 10450 (54.9%) 0.36876
Primary hip diagnosis    
Primary arthrosis 5646 (62.3%) 15588 (81.9%) 0.40642
Trauma 2546 (28.1%) 1628 (8.6%) 0.48898
Other 871 (9.6%) 1808 (9.5%) 0.02348
Comorbidity history (yes)    
Myocardial infarction 491 (5.4%) 717 (3.8%) 0.07073
Congestive heart failure 612 (6.8%) 600 (3.2%) 0.17886
Peripheral vascular disease 442 (4.9%) 645 (3.4%) 0.05825
Cerebrovascular disease 990 (10.9%) 1010 (5.3%) 0.22239
Dementia 165 (1.8%) 106 (0.6%) 0.11135
Chronic pulmonary disease 815 (9.0%) 1227 (6.5%) 0.09349
Connective tissue disease 679 (7.5%) 972 (5.1%) 0.11434
Peptic ulcer disease 654 (7.2%) 745 (3.9%) 0.15010
Mild liver disease 167 (1.8%) 214 (1.1%) 0.05590
Diabetes (type I and II) 544 (6.0%) 764 (4.0%) 0.08144
Hemiplegia 19 (0.2%) 19 (0.1%) 0.01715
Moderate to severe renal disease 236 (2.6%) 229 (1.2%) 0.13977
Diabetes with end organ damage 274 (3.0%) 326 (1.7%) 0.10146
Any tumor 1151 (12.7%) 1637 (8.6%) 0.16577
Leukemia 36 (0.4%) 35 (0.2%) 0.05114
Lymphoma 69 (0.8%) 76 (0.4%) 0.06085
Moderate to severe liver disease 63 (0.7%) 39 (0.2%) 0.07666
Metastatic solid tumor 141 (1.6%) 121 (0.6%) 0.11523
Fixation technique    
Cemented 4060 (44.8%) 6170 (32.4%) 0.26193
Cementless 2118 (23.4%) 7486 (39.4%) 0.37578
Hybrid 2885 (31.8%) 5368 (28.2%) 0.09093
Type of anesthesia    
Regional 5929 (65.4%) 14622 (76.9%) 0.29165
Universal and Combined 3134 (34.6%) 4402 (23.1%) 0.29165
Duration of surgery (minutes)    
0-60 1819 (20.1%) 7439 (39.1%) 0.34220
61-120 6199 (68.4%) 11097 (58.3%) 0.10558
>121 1045 (11.5%) 488 (2.6%) 0.34021
20 hospitals performing the THR procedures*   
Prophylaxis for heterotopic bone formations **   
Yes 600 (6.6%) 1317 (6.9%) 0.01945
No 8463 (93.4%) 17707 (93.1%) 0.02058
Year of surgery    
1999 114 (1.3%) 115 (0.6% 0.10403
2000 731 (8.1%) 764 (4.0%) 0.11245
2001 623 (6.9%) 1353 (7.1%) 0.05878
2002 1123 (12.4%) 1757 (9.2%) 0.19310
2003 989 (10.9%) 1669 (8.8% 0.13441
2004 1103 (12.2%) 2570 (13.5%) 0.01450
2005 1410 (15.6%) 3148 (16.6%) 0.08021
2006 1579 (17.4%) 3820 (20.1%) 0.19120
2007 1390 (15.4%) 3828 (20.1%) 0.12261
  1. Data are shown in number (%) unless otherwise specified. * Each of the 20 hospitals performing the THR procedures was treated as separate covariate. ** Anti -rheumatic drugs were used as prophylaxis for heterotopic bone formation. *** A standardized mean difference that exceeds 0.1 is indicative of significant imbalance between groups.